Eyenovia, Inc.

As of March 30, 2023, Eyenovia, Inc. is considered overvalued with negative financial metrics, including a price-to-book value of -1.45 and an EV to EBITDA of -0.78, and has underperformed significantly with a year-to-date return of -53.08%.

As of June 18, 2025, the market trend is mildly bullish, supported by weekly MACD and OBV indicators, despite some bearish signals on the monthly Bollinger Bands and moving averages.

As of March 2022, the management team of Eyenovia, Inc. includes Dr. Fredric Eshelman (Independent Chairman), Dr. Tsontcho Ianchulev (CEO, Director, Chief Medical Officer), and several Independent Directors: Dr. Curt Labelle, Mr. Kenneth Lee, Dr. Ernest Mario, Mr. Charles Mather, and Dr. Anthony Sun. This team oversees the company's strategic direction and operations.

Eyenovia, Inc. is a clinical stage biopharmaceutical company focused on developing micro-dose therapeutics. As of March 2025, it reported net sales of $0 million and a net loss of $3 million, with a market cap of $20.09 million.

As of Jun 18, Eyenovia, Inc. has a market capitalization of 20.09 million, with net sales of 0.06 million and a net profit of -42.37 million over the last four quarters. Shareholder's funds are reported at -13.10 million, and total assets amount to 3.67 million.